ZBIO

Zenas BioPharma, Inc. Common Stock

ZBIO

Market cap $768M

Overview Fund Activity

19.07 USD

+0.83

4.55%

At close Updated Sep 17, 4:00 PM EDT

1 day

4.55%

5 days

-3.54%

1 month

10.36%

3 months

97%

6 months

126.22%

Year to date

111.65%

1 year

8.17%

5 years

5.07%

10 years

5.07%

About: Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Employees: 130

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

183% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 12

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

29% more capital invested

Capital invested by funds: $257M [Q1] → $330M (+$73.3M) [Q2]

7% more funds holding

Funds holding: 67 [Q1] → 72 (+5) [Q2]

3.66% more ownership

Funds ownership: 77.75% [Q1] → 81.41% (+3.66%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

See Fund Rankings

Financial journalist opinion

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept.

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases, today announced management's presentations at the following investor conferences in September:

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

Zenas BioPharma, Inc.'s Obexelimab offers a differentiated, non-depleting B-cell inhibition approach, with promising Phase 2 data in IgG4 and upcoming pivotal catalysts in 2025. The lead asset's blockbuster potential hinges on positive Phase 3 IgG4 results, with analysts projecting peak sales over $1.5bn if approved. ZBIO risks include obexelimab's prior Phase 2 failure in lupus nephritis and limited pipeline depth, but strong cash reserves support near-term operations.

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on June 16, 2025 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 112,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

Investors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=153372&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq.

Investors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)

ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas BioPharma” or “the Company”) (NASDAQ: ZBIO) and certain of its officers.

ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $ZBIO--ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

See News Rankings

Charts implemented using Lightweight Charts™